Radiodermatitis, commonly known as radiation-induced skin reactions, is an acute side effect that popularly occurs in cancer patients at some point during their radiation therapy. Alternatively, chronic radiodermatitis may surface post-treatment after several months or years. The acute reactions are a common phenomenon among cancer patients undergoing some sort of radiation therapy. In addition, in a small number of populations affected, these skin reactions are caused by nuclear radiations.
Get Report Sample @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2157
Although, in most cases, the conditions may subside over time, late-onset radiodermatitis is a cause of marked morbidity in patient populations. It not only affects the efficacy of subsequent therapeutic modalities used by clinicians but also have significant repercussions on the quality of life.
Which trends underpin substantial prospects in radiodermatitis treatment?
While the treatment modalities and therapies focused on reducing radiodermatitis reactions are still emerging, radiation therapies used on cancer patients are also undergoing substantial advances. Some of the major products used in the treatment are topical products including antibiotics, corticosteroid creams, and hydrophilic creams. The rising prevalence of various cancer types and relentless industry efforts to bring innovation in technologies to control the underlying symptoms and manage acute or chronic radiodermatitis. Companies are also tapping into avenues in emerging markets characterized by vast unmet medical needs.
With ample opportunities in the offing, the global radiodermatitis market is projected to touch a valuation of US$421.5 by 2024 end, garnering a CAGR of 3.90% in between the period from 2016 to 2024, according to estimates by Transparency Market Research.
A number of clinical trials are being conducted in developed nations, notably in U.S., for evaluating the potential of low-level laser therapy on treating radiodermatitis. These are focused on developing universally-acceptable evidence-based treatment modality for cancer patients suffering from acute radiodermatitis, particularly in head and neck region. Such studies play a key role in driving the current trajectory of research activities in the market.
Which are the regions expected to present significant promising avenues, contributing attractive revenues to global market?
Europe as well as North America are robust regional markets for radiodermatitis. The growth is broadly driven by incessant research and development activities, a spate of innovative product launches in recent years, and substantial, constant support by government institutes. Furthermore, the presence of a copious number of prominent pharmaceutical companies is aiding in the substantial expansion.
On the other hand, Asia Pacific is home to ample promising opportunities for market players. A notably swelling patient populations in several of its key economies, coupled with the rising incidence of acute radiodermatitis conditions, contribute to a burgeoning demand for treatments.